Canadian sanitizer firm receives NDC
This article was originally published in The Rose Sheet
Executive Summary
British Columbia-based Alda Pharmaceuticals receives a National Drug Code from FDA, allowing the firm to sell its OTC monograph products, including its T36 antimicrobial products, in the U.S., the firm reports April 7. "This is the first step in fulfilling our strategy of securing foreign sales for current products while we continue to pursue the testing and registration" of therapeutic products with T36, the company says. Alda's T36 technology is touted as having distinct advantages over typical alcohol hand sanitizers because it kills a "wider range" of infectious organisms and lasts for hours on skin to provide continuous protection, according to the firm